 AstraZeneca PLC LSE:AZN has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCors cash and marketable securities, valued at US522mln late September. 